ClinicalTrials.gg
RecruitingNCT06301438Updated Feb 3, 2026

Dalpiciclib in HR+/HER2- ABC

An observational study in Advanced Breast Cancer, sponsored by RenJi Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-03.

Sponsored by RenJi Hospital · Observational

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
103
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Breast Neoplasms by RenJi Hospital — 15 open to participants now, 17 under way, 2 of them phase 3. Breast Neoplasms · RenJi Hospital.

Started
2024
with 2 others
Observational
7 of 20
6 open now
Primary completion
2027-01
later than 11 of 16 live
Registered
16th of 20
by date

Among the 20 studies in Breast Neoplasms by RenJi Hospital, this one is one of 3 that started in 2024, is one of 7 observational ones, reaches primary completion later than 11 of the 16 other live ones, and was the 16th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

15 of the 20 studies in Breast Neoplasms by RenJi Hospital are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Breast Neoplasms by RenJi Hospital, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of dalpiciclib in patients with HR-positive/HER2-positive advanced breast cancer.

03

Conditions studied

  • Advanced Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed advanced breast cancer
  • Hormone receptor-positive and human epidermal growth factor receptor 2-negative
  • 0-1

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding
  • History of immunodeficiency
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
103 participants (estimated)
Patient registry
No

Groups and cohorts

  • dalpiciclib

    dalpiciclib oral day 1-21, every 28 days

    Drug: dalpiciclib

Interventions

  • dalpiciclib oral day 1-21, every 28 days

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival

    The time from the date of starting dalpiciclib to the date of disease progression as per RECIST version 1.1 or death from any cause, whichever occurs first.

    Time frame: From the date of starting dalpiciclib to the date of first documentation of progression or death (up to approximately 1 years)

Secondary outcomes

  1. Adverse events

    Adverse events during dalpiciclib treatment will be assessed according to the NCI CTCAE v5.0.

    Time frame: From the date of starting dalpiciclib to the end of the treatment (up to approximately 1 year)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Jan 2027, 32 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 32 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2024
First posted
Mar 8, 2024
StartActual
May 3, 2024
Primary completionEst.
Jan 2027
CompletionEst.
Dec 2028
Last update
Feb 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06301438
Lead sponsor
RenJi Hospital
Responsible party
Wenjin Yin (Deputy Chief of Breast Surgery Department, RenJi Hospital) — Principal investigator
First posted
Mar 8, 2024
Start date
May 3, 2024
Primary completion
Jan 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Feb 3, 2026

Study contacts

Wenjin Yin
Contact
yinwenjin@renji.com
86(21)68385569
Wenjin Yin
principal investigator · Renji Hospital, School of Medicine, Shanghai Jiaotong University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion